Enter your ZIP code:

Please enter a 5 digit zipcode
No results...

Entering your zip code helps us to provide information and results that are more relevant to you.

Your privacy is important to us. By continuing, you agree to our Privacy Policy.





Prospective Evaluation of Efficacy of CMV-specific T Cell Immunity (CMV-TCIP) Directed Letermovir Prophylaxis after Allogeneic Hematopoietic Cell Transplantation

Cancer
Piyanuch Kongtim
Hodgkin's Lymphoma
Leukemia other
Lymphoid Leukemia
Multiple Myeloma
Myeloid and Monocytic Leukemia
Non-Hodgkin's Lymphoma
Other Hematopoietic

Study Description

This is a phase 2, prospective cohort clinical trial evaluating the utilization of CMV T Cell Immunity Panel (CMV-TCIP) assay to guide the duration of primary CMV prophylaxis in CMV-seropositive recipients of allogeneic stem cell transplant or recipients receiving a stem cell graft from a CMV serology positive donor.

Eligibility

You can participate in this study if you satisfy the following criteria:

  1. Are at least 18 years of age or older
  2. Confirmed tested positive for CMV (either the donor or recipient) before undergoing Allogeneic Hematopoietic Cell Transplantation (AHCT)

You cannot participate in this study if you have any of the following criteria:

  1. Have a history of CMV end-organ disease OR CS-CMVi within 6 months of enrollment
  2. Any uncontrolled infection
  3. Have a known or suspected hypersensitivity to letermovir
  4. Have received within 30 days of screening OR planning to take during the study any of the following: cidofovir, CMV hyper-immune globulin, or any investigational CMV antiviral agent / biologic therapy
A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.